Novartis Alters Zometa Study Design Due To Renal Function Concerns

Novartis is eliminating the 8 mg Zometa arm of its ongoing bone metastases studies, following the detection of elevated serum creatinine levels in some patients.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet